Global Overactive Bladder OAB Therapeutics Market by Type (Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists), By Application (Hosptial, Clinci, Other) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Overactive Bladder (OAB) Therapeutics Market size is projected to reach USD 1.6 billion by 2028. The OAB market has been dominated by the US and European markets since 2015, owing to their high prevalence of urinary incontinence among patients and increasing awareness about treatments for it. It is also anticipated that the Asia Pacific region will experience exponential growth in the coming years due to its large population base and improving healthcare infrastructure.
An overactive bladder (OAB) is a urinary disorder in which the muscles that control urination are too active. OAB symptoms may include an urgent need to go, leakage of urine, and wetting accidents outside of the toilet or during sleep. Overactive bladder treatments can help manage these symptoms with medication and devices like catheters and alarms.
On the basis of Types, the market is segmented into anticholinergic agents and beta-3 adrenoreceptor agonists.
Anticholinergic Agents:
Anticholinergic agents are medications that block the action of acetylcholine, a neurotransmitter found in nerve cells. These drugs work by making it harder for muscles around the bladder neck to contract and relax. Anticholinergic agents help patients with overactive bladders control their urinary frequency and urgency symptoms.
Beta-3 Adrenoreceptor Agonists:
beta-adrenoreceptor agonists are a group of medications that help relax the muscles around the bladder neck, which can make it easier for patients to control their urinary frequency and urgency symptoms. beta-adrenoreceptor agonists work by stimulating beta receptors in response to nerve signals sent from the brain. These drugs increase blood flow into the cells lining the bladder wall, making them less sensitive so they do not contract quite as much when stimulated.
On the basis of Application, the market is segmented into hospitals and clinics.
Hospitals:
In hospitals, beta-adrenoreceptor agonists can be used in the treatment of postoperative urinary retention. These drugs are widely regarded as an important part of a multidisciplinary approach to managing patients with upper urinary tract obstruction (UTO).
beta-adrenoreceptor agonists have also been shown to reduce catheterization frequency by over 30% and increase spontaneous voiding rates. This is especially useful for elderly or frail populations who would otherwise require frequent bladder emptying procedures that pose risks such as urethral injury.
Clinics:
Clinics may use anticholinergic agents to help manage patients with overactive bladder, although these drugs are not recommended as monotherapy. Anticholinergics act by blocking the transmission of a neurotransmitter called acetylcholine from one neuron to another in the body. This blocks several functions such as urine flow and sphincter muscle contraction.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominates in terms of the number of patients suffering from Overactive Bladder (OAB). This region has been driven by technological advancements in the healthcare sector as well as increasing awareness about health issues like chronic diseases among people
Latin America is expected to grow at the fastest rate in this market during 2021-2028. This growth can be attributed to increasing awareness about chronic diseases and its managements, rising healthcare expenditure as well as lack of competition from generic drug manufacturers which has made them comparatively inexpensive than branded counterparts in the region.
Growth Factors For The Overactive Bladder OAB Therapeutics Market:
-The increasing prevalence of bladder-related disorders associated with aging coupled with improved awareness about the management of these conditions will drive growth in this market.
-Increasing incidence rates and prevalence of chronic diseases such as diabetes, obesity, arthritis among others which are often accompanied by OAB symptoms can be a major driver for this market from 2021 to 2028.
-Technological advancements are expected to help increase the adoption rate for new treatment modalities thereby driving growth in this segment. Innovations in PET scan technology have led to faster diagnosis of various cancers including those affecting urinary tract organs like prostate cancer that was once difficult to detect whereas MRI scanners have helped improve the delivery of minimally invasive surgical treatments without jeopardizing patient safety.
-Technological developments in diagnostic imaging techniques are expected to be a major factor that will contribute towards the development and adoption of new treatment methods.
Up Market Research published a new report titled “Overactive Bladder OAB Therapeutics Market research report which is segmented by Types (Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists), By Applications (Hosptial, Clinci, Other), By Players/Companies Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries”.
Report Scope
| Report Attributes | Report Details |
| Report Title | Overactive Bladder OAB Therapeutics Market Research Report |
| By Type | Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists |
| By Application | Hosptial, Clinci, Other |
| By Companies | Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, ONO Pharmaceutical, Sanofi, Tengion, Teva Pharmaceutical Industries |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 218 |
| Number of Tables & Figures | 153 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Overactive Bladder OAB Therapeutics Market Report Segments:
The market is segmented by Type Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists and By Application Hosptial, Clinci, Other.
Some of the companies that are profiled in this report are:
- Allergan
- Astellas Pharma
- Hisamitsu Pharmaceutical
- Pfizer
- Ferring
- GlaxoSmithKline
- Ion Channel Innovations
- Kwang Dong Pharmaceutical
- Lanzhou Institute of Biological Products
- Merck
- ONO Pharmaceutical
- Sanofi
- Tengion
- Teva Pharmaceutical Industries
Overactive Bladder OAB Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Overactive Bladder OAB Therapeutics Market
Overview of the regional outlook of the Overactive Bladder OAB Therapeutics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Overactive Bladder OAB Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Overactive Bladder OAB Therapeutics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Anticholinergic Agents
2. Beta-3 Adrenoreceptor Agonists
7. By Application:1. Hosptial
2. Clinci
3. Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Overactive Bladder OAB Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Overactive Bladder OAB Therapeutics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Overactive Bladder OAB Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Overactive Bladder OAB Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Overactive Bladder OAB Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Overactive Bladder OAB Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Overactive Bladder OAB Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Overactive Bladder OAB Therapeutics Market Size and Y-o-Y Growth
4.5.2 Overactive Bladder OAB Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Type
5.2.1 Anticholinergic Agents
5.2.2 Beta-3 Adrenoreceptor Agonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
6.2.1 Hosptial
6.2.2 Clinci
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Overactive Bladder OAB Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Type
9.6.1 Anticholinergic Agents
9.6.2 Beta-3 Adrenoreceptor Agonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
9.10.1 Hosptial
9.10.2 Clinci
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Overactive Bladder OAB Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Type
10.6.1 Anticholinergic Agents
10.6.2 Beta-3 Adrenoreceptor Agonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
10.10.1 Hosptial
10.10.2 Clinci
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Overactive Bladder OAB Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Type
11.6.1 Anticholinergic Agents
11.6.2 Beta-3 Adrenoreceptor Agonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
11.10.1 Hosptial
11.10.2 Clinci
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Overactive Bladder OAB Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Type
12.6.1 Anticholinergic Agents
12.6.2 Beta-3 Adrenoreceptor Agonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
12.10.1 Hosptial
12.10.2 Clinci
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Type
13.6.1 Anticholinergic Agents
13.6.2 Beta-3 Adrenoreceptor Agonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
13.10.1 Hosptial
13.10.2 Clinci
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Overactive Bladder OAB Therapeutics Market: Competitive Dashboard
14.2 Global Overactive Bladder OAB Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Astellas Pharma
14.3.3 Hisamitsu Pharmaceutical
14.3.4 Pfizer
14.3.5 Ferring
14.3.6 GlaxoSmithKline
14.3.7 Ion Channel Innovations
14.3.8 Kwang Dong Pharmaceutical
14.3.9 Lanzhou Institute of Biological Products
14.3.10 Merck
14.3.11 ONO Pharmaceutical
14.3.12 Sanofi
14.3.13 Tengion
14.3.14 Teva Pharmaceutical Industries
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Overactive Bladder OAB Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Overactive Bladder OAB Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Overactive Bladder OAB Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Overactive Bladder OAB Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Overactive Bladder OAB Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Overactive Bladder OAB Therapeutics Market Size and Y-o-Y Growth
4.5.2 Overactive Bladder OAB Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Type
5.2.1 Anticholinergic Agents
5.2.2 Beta-3 Adrenoreceptor Agonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
6.2.1 Hosptial
6.2.2 Clinci
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Overactive Bladder OAB Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Overactive Bladder OAB Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Overactive Bladder OAB Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Type
9.6.1 Anticholinergic Agents
9.6.2 Beta-3 Adrenoreceptor Agonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
9.10.1 Hosptial
9.10.2 Clinci
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Overactive Bladder OAB Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Type
10.6.1 Anticholinergic Agents
10.6.2 Beta-3 Adrenoreceptor Agonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
10.10.1 Hosptial
10.10.2 Clinci
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Overactive Bladder OAB Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Type
11.6.1 Anticholinergic Agents
11.6.2 Beta-3 Adrenoreceptor Agonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
11.10.1 Hosptial
11.10.2 Clinci
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Overactive Bladder OAB Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Type
12.6.1 Anticholinergic Agents
12.6.2 Beta-3 Adrenoreceptor Agonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
12.10.1 Hosptial
12.10.2 Clinci
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Type
13.6.1 Anticholinergic Agents
13.6.2 Beta-3 Adrenoreceptor Agonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Overactive Bladder OAB Therapeutics Market Size Forecast by Applications
13.10.1 Hosptial
13.10.2 Clinci
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Overactive Bladder OAB Therapeutics Market: Competitive Dashboard
14.2 Global Overactive Bladder OAB Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Astellas Pharma
14.3.3 Hisamitsu Pharmaceutical
14.3.4 Pfizer
14.3.5 Ferring
14.3.6 GlaxoSmithKline
14.3.7 Ion Channel Innovations
14.3.8 Kwang Dong Pharmaceutical
14.3.9 Lanzhou Institute of Biological Products
14.3.10 Merck
14.3.11 ONO Pharmaceutical
14.3.12 Sanofi
14.3.13 Tengion
14.3.14 Teva Pharmaceutical Industries
Segments Covered in the Report
The global Overactive Bladder OAB Therapeutics market has been segmented based on
By Types
The global Overactive Bladder OAB Therapeutics market has been segmented based on
By Types
- Anticholinergic Agents
- Beta-3 Adrenoreceptor Agonists
- Hosptial
- Clinci
- Other
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Allergan
- Astellas Pharma
- Hisamitsu Pharmaceutical
- Pfizer
- Ferring
- GlaxoSmithKline
- Ion Channel Innovations
- Kwang Dong Pharmaceutical
- Lanzhou Institute of Biological Products
- Merck
- ONO Pharmaceutical
- Sanofi
- Tengion
- Teva Pharmaceutical Industries
Our Clients
Related Reports
Some other reports from this category!
